An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Acronyms RECAP
  • Sponsors Genentech; InterMune
  • Most Recent Events

    • 24 May 2017 Safety findings from pooled trial databases (NCT00662038, NCT02699879 and NCT02141087); resultpresented at the 113th International Conference of the American Thoracic Society
    • 13 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 12 May 2014 According to an InterMune media release, a comprehensive analysis of safety of this and 3 other clinical trials (244346, 244349 and 244526) will be presented at the 2014 American Thoracic Society Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top